Equillium, Inc. (EQ)

Market Cap	14.36M
Revenue (ttm)	41.10M
Net Income (ttm)	-8.07M
Shares Out	35.43M
EPS (ttm)	-0.23
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	425,983
Open	0.4519
Previous Close	0.4880
Day's Range	0.3655 - 0.4636
52-Week Range	0.3655 - 2.4300
Beta	1.87
Analysts	Buy
Price Target	3.00 (+640.01%)
Earnings Date	Mar 27, 2025

About EQ

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company’s lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lu...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 11, 2018
• Employees: 44
• Stock Exchange: NASDAQ
• Ticker Symbol: EQ
• Website: https://www.equilliumbio.com

Financial Performance

In 2024, Equillium's revenue was $41.10 million, an increase of 13.89% compared to the previous year's $36.08 million. Losses were -$8.07 million, -39.51% less than in 2023.

Analyst Forecast

According to 3 analysts, the average rating for EQ stock is "Buy." The 12-month stock price forecast is $3.0, which is an increase of 640.01% from the latest price.

Price Target

$3.0

(640.01% upside)

Analyst Consensus: Buy